Haemonetics (HAE) Loses -5.16% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Core Insights - Haemonetics (HAE) has experienced significant selling pressure, resulting in a 5.2% decline over the past four weeks, but analysts anticipate better earnings than previously predicted, indicating potential for recovery [3]. Group 1: Technical Indicators - The Relative Strength Index (RSI) for HAE is currently at 29.65, suggesting that the stock is in oversold territory and may be due for a rebound as selling pressure could be exhausting [5]. - RSI is a momentum oscillator that ranges from 0 to 100, with readings below 30 typically indicating that a stock is oversold [5]. Group 2: Fundamental Indicators - There has been a strong consensus among sell-side analysts to raise earnings estimates for HAE, leading to a 0.4% increase in the consensus EPS estimate over the last 30 days [2]. - HAE holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, indicating a strong potential for price appreciation [2].